A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer

Annals of Oncology

Volumn 9, Issue 4, 1998, Pages 457-459

  Castellano, D ^a   Lianes, P ^a   Paz Ares, L ^a   Hidalgo, M ^a   Guerra, J A ^a   Gomez Martin C ^a   Gomez H ^a   Calzas, J ^a   Cortes Funes H ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Chemotherapy; Gemcitabine; New drugs; Non small cell lung cancer

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031799671     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008276507236     Document Type: Article

References (14)

1. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992; 327: 1434-41.
2. Non Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small: A meta-analysis using update data on individual patients from 52 randomized clinical trials. BMJ 1995; 7: 899-909.
3. Plunket W, Huang P, Searcy C, Gandhi V. Gemcitabine: Preclinical, pharmacology and mechanisms of action. Semin Oncol 1996; 23 (Suppl 10): 3-15.
4. Hertel LW, Boder GB, Kroin JS et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990; 50: 4417-22.
5. Abbruzzesc JL, Grunewald R, Weebs EA et al. A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491-8.
6. Gatzemier U, Sheperd FA, Le-Chevalier T et al. Activity of gemcitabine in patients with non-small cell lung cancer: A multicenter extended phase II study. Eur J Cancer 1996; 32: 243-8.
7. Peters GJ, Ruiz van Haperen VWT, Bergman AM et al. Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol 1996; 23 (Suppl 10): 16-24.
8. Hryniuk W. The importance of dose intensity in outcome of chemotherapy. In De Vita VTJ, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia. PA: Lippincott 1988; 121-41.
9. Shepherd FA, Burkes RL, Cormier Y et al. Final results of the Canadian phase I dose escalation trial of gemcitabine and cisplatin for advanced non-small cell lung cancer. Semin Oncol 1996; 23 (Suppl 10): 48-54.
10. Abratt RP, Bezwoda WR, Goedhals L et al. Weekly gemcitabine with monthly cisplatin: Effective chemotherapyfor advanced non-small cell lung cancer. J Clin Oncol 1997; 15: 744-9.
11. Steward PW, Dunlop DJ, Dabouis G et al. Phase II study of gemcitabine and cisplatin in the treatment of advanced non-smal cell lung cancer: Preliminary results. Semin Oncol 1996; 23 (Suppl 10): 43-7.
12. Crinó L. Scagliotti G, Marangolo M et al. Cisplatin-gemcitabine combination in advanced non-small cell lung cancer: A phase II study. J Clin Oncol 1997; 15: 297-303.
13. Sandler A, Ansari R, McClean J et al. Gemcitabine plus cisplatin in non-small cell lung cancer: A phase II study. Proc Am Soc Clin Oncol 1995; 14: 225 (Abstr 1079).
14. Cardenal F, Rosell R, Antón A et al. Gemcitabine and cisplatin vs. etoposide and cisplatin in advanced non-small cell lung cancer (NSCLC) patients: Preliminary randomized phase III results. Proc Am Soc Clin Oncol 1997; 16: 458 (Abstr 1648).